Literature DB >> 8528726

SIV infection of monkey spleen cells including follicular dendritic cells in different stages of disease.

I Stahmer1, C Ordonez, M Popovic, R Mesquita, M Ekman, J Albert, P Putkonen, D Böttiger, G Biberfeld, P Biberfeld.   

Abstract

Immunoaffinity enriched spleen follicular dendritic cells (FDCs), lymphocytes, and macrophages from SIVsm-inoculated cynomolgus monkeys (Macaca fascicularis) at different stages of disease were compared for latent and productive SIV infection. Analysis of FDCs by in situ hybridization, electron microscopy, and coculture assays indicated that comparatively high levels of virus were associated with the FDC fraction. Polymerase chain reaction (PCR) and RT-PCR results revealed that the levels for SIVpol DNA did not correlate with the level of env mRNA in the various cell subsets, suggesting differences in latency. Limiting dilution assays for spliced env mRNA showed a 10-100-fold higher amount of env mRNA in FDCs than in other spleen cell subsets early during SIV infection. At late stages of disease, the number of productively infected FDCs significantly decreased in parallel with a marked reduction of the FDC network and follicular involution. Our findings indicate that destruction of FDCs probably reflects a cytopathic effect of SIV and/or the activity of specific antiviral cytotoxic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8528726     DOI: 10.1097/00042560-199601010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  2 in total

1.  Follicular dendritic cells productively infected with immunodeficiency viruses transmit infection to T cells.

Authors:  R Sprenger; K M Toellner; C Schmetz; W Lüke; C Stahl-Hennig; M Ernst; G Hunsmann; H Schmitz; H D Flad; J Gerdes
Journal:  Med Microbiol Immunol       Date:  1995-10       Impact factor: 3.402

2.  Jaundice in African-American and Hispanic patients with AIDS.

Authors:  Abbasi J Akhtar; Magda Shaheen
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.